Loading clinical trials...
Loading clinical trials...
Change in Serum Levels of NT-proBNP During Triple Therapy With Formoterol/Glycopyrrolate/Budesonide in Patients With COPD.
Observational prospective study to evaluate serum NT-proBNP levels in a population of COPD patients three months after the iniation of triple inhaled formoterol/glycopyrrolate/budesonide therapy.
The purpose of the trixeo study is to conduct a prospective observational study to evaluate serum NT-proBNP levels in a population of COPD patients three months after the initiation of triple inhaled formoterol/glycopyrrolate/budesonide therapy.
Age
50 - No limit years
Sex
ALL
Healthy Volunteers
No
INRCA Hospital
Ancona, Italy
IRCCS INRCA Hospital
Osimo, Italy
Start Date
June 28, 2022
Primary Completion Date
December 31, 2025
Completion Date
December 31, 2025
Last Updated
March 19, 2024
29
ESTIMATED participants
Lead Sponsor
Istituto Nazionale di Ricovero e Cura per Anziani
NCT07477600
NCT07462221
NCT07351929
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions